2

1

2

3

4

5

	WHAT IS CLAIMED IS:		
1	1. A method of inhibiting expression of an endogenous cellular gene		
2	in a cell, the method comprising the step of:		
3	contacting a first target site in the endogenous cellular gene with a first		
4	zinc finger protein, wherein the K <sub>d</sub> of the zinc finger protein is less than about 25 nM;		
5	thereby inhibiting expression of the endogenous cellular gene by at least		
6	about 20%.		
1 ·	2. The method of claim 1, wherein the step of contacting further		
2	comprises contacting a second target site in the endogenous cellular gene with a second		
3	zinc finger protein.		
1	3. The method of claim 2, wherein the first and second target sites an		
2	adjacent.		
1	4. The method of claim 3, wherein the first and second zinc finger		
2	proteins are covalently linked.		
1	5. The method of claim 1, wherein the first zinc finger protein is a		
2	fusion protein comprising a regulatory domain.		
1	6. The method of claim 5, wherein the first zinc finger protein is a		
2	fusion protein comprising at least two regulatory domains.		
1	7. The method of claim 2, wherein the first and second zinc finger		
2	proteins are fusion proteins, each comprising a regulatory domain.		

The method of claim 7, wherein the first and second zinc finger 8. protein are fusion proteins, each comprising at least two regulatory domains.

A method of inhibiting expression of an endogenous cellular gene 9. in a cell, the method comprising the step of:

contacting a target site in the endogenous cellular gene with a fusion zinc finger protein comprising six fingers and a regulatory domain, wherein the  $K_{\text{\scriptsize d}}$  of the zinc finger protein is less than about 25 nM;

6		hereby	inhibiting expression of the endogenous cellular gene by at least
7	about 20%.		
1			The method of claim 1, wherein the cell is selected from the group ell, a plant cell, a bacterial cell, a protozoal cell, or a fungal cell.
2	consisting of an	ıımaı c	en, a piant cen, a bacterial cen, a protozoal cen, or a rangar con.
1	1	11.	The method of claim 10, wherein the cell is a mammalian cell
1	1	12.	The method of claim 11, wherein the cell is a human cell.
1	:	13.	The method of claim 1, wherein expression of the endogenous
2	cellular gene is	inhibi	ted by at least about 75%-100%.
1		14.	The method of claim 1, wherein the endogenous cellular gene is a
2	selected from the group consisting of VEGF, ERa, IGF-I, c-myc, c-myb, ICAM, and		
3	Her2/Neu.		
			W. Constant
1		15.	The method of claim 1, wherein the endogenous cellular gene is
2	VEGF.		
1		16.	The method of claim 1, wherein the inhibition of gene expression
2	prevents gene activation.		
1		17.	The method of claim 5 or 7, wherein the regulatory domain is
2	selected from t	he gro	up consisting of a transcriptional repressor, an endonuclease, a
3	methyl transferase, and a histone deacetylase.		
		,	
1		18.	The method of claim 1, wherein the method further comprises the
2	step of first add	ministe	ering to the cell a delivery vehicle comprising the zinc finger protein,
3	wherein the de	livery	vehicle comprises a liposome or a membrane translocation
4	polypeptide.		
1		19.	The method of claim 1, wherein the zinc finger protein is encoded
2	by a zinc finge	r prote	in nucleic acid operably linked to a promoter, and wherein the
3			rises the step of first administering the nucleic acid to the cell in a

lipid:nucleic acid complex or as naked nucleic acid.

1	20.	The method of claim 1, wherein the zinc finger protein is encoded	
2	by an expression vect	or comprising a zinc finger protein nucleic acid operably linked to a	
3	promoter, and wherei	n the method further comprises the step of first administering the	
4	expression vector to t	he cell.	
	21	The south of a fair 20 ask again the expression vector is a viral	
1	21.	The method of claim 20, wherein the expression vector is a viral	
2	expression vector.	. •	
1	22.	The method of claim 20, wherein the expression vector is a	
2	retroviral expression	vector, an adenoviral expression vector, a DNA plasmid expression	
3	vector, or an AAV expression vector.		
	22	The method of claim 20, wherein the zinc finger protein is encoded	
1	23.	rably linked to an inducible promoter.	
2	by a nucleic acid ope	racity infixed to an inductore promoter.	
1	24.	The method of claim 20, wherein the zinc finger protein is encoded	
2	by a nucleic acid ope	rably linked to a weak promoter.	
	25	my d. 1. C. L.	
1	$25.$ $1.5 \times 10^6$ copies of the	The method of claim 1, wherein the cell comprises less than about	
2	1.5x10 copies of the	zinc tinger protein.	
1	26.	The method of claim 1, wherein the target site is upstream of a	
2	transcription initiation	n site of the endogenous cellular gene.	
	2.5		
1	27.	The method of claim 1, wherein the target site is adjacent to a	
2	transcription initiation	on site of the endogenous cellular gene.	
1	28.	The method of claim 1, wherein the target site is adjacent to an	
2	RNA polymerase pa	use site downstream of a transcription initiation site of the	
3	endogenous cellular	gene.	
	20	The state of the s	
1	29.	The method of claim 1, wherein the zinc finger protein comprises	
2	an SP-1 backbone.		

30.

a regulatory domain and is humanized.

The method of claim 29, wherein the zinc finger protein comprises

about 150%.

1		31.	A method of activating expression of an endogenous cellular gene
2	the method co	omprisi	ng the step of:
3		contac	cting a first target site in the endogenous cellular gene with a first
4	zinc finger pr	otein, v	wherein the K <sub>d</sub> of the zinc finger protein is less than about 25 nM;
5		thereb	by activating expression of the endogenous cellular gene to at least
6	about 150%.		
		22	The method of claim 31, wherein the step of contacting further
1		32.	
2	•	_	g a second target site in the endogenous cellular gene with a second
3	zinc finger pr	otein.	
1		33.	The method of claim 32, wherein the first and second target sites
2	are adjacent.		
	•		
1		34.	The method of claim 33, wherein the first and second zinc finger
2	proteins are c	ovalent	ily linked.
1		35.	The method of claim 31, wherein the first zinc finger protein is a
2	fusion proteir		rising a regulatory domain.
2	rasion protein	Compi	ising a regulatory domain.
1		36.	The method of claim 35, wherein the first zinc finger protein is a
2	fusion proteir	ı compi	rising at least two regulatory domains.
1		37.	The method of claim 32, wherein the first and second zinc finger
			·
2	proteins are i	usion p	roteins, each comprising a regulatory domain.
1		38.	The method of claim 37, wherein the first and the second zinc
2	finger protein	are fus	sion proteins, each comprising at least two regulatory domains.
1		39.	A method of activating expression of an endogenous cellular gene
2	the method co	_	ng the step of:
3		conta	cting a target site in the endogenous cellular gene with a fusion zinc
4	finger proteir	compr	rising six fingers and a regulatory domain, wherein the $K_{\text{d}}$ of the zin
5	finger protein		than about 25 nM;
6		therel	by activating expression of the endogenous cellular gene to at least

:

1		40.	The method of claim 31, wherein the cell is selected from the
2	group consistir	ig of ar	n animal cell, a plant cell, a bacterial cell, a protozoal cell, or a
3	fungal cell.		
1		41.	The method of claim 40, wherein the cell is a mammalian cell.
1		42.	The method of claim 41, wherein the cell is a human cell
1		43.	The method of claim 31, wherein expression of the endogenous
2	cellular gene is activated to at least about 200-500%.		
1		44.	The method of claim 31, wherein the endogenous cellular gene is a
2	selected from the group consisting of FAD2-1, EPO, GM-CSF, GDNF, VEGF, and LDL		
3	R.		
1		45.	The method of claim 31, wherein the endogenous cellular gene is
2	VEGF.	75.	The method of claim 31, wherein the endogenous centural gene is
-	TEGI.		
1		46.	The method of claim 31, wherein the activation of gene expression
2	prevents repres	sion of	gene expression.
1		47.	The method of claim 35 or 37, wherein the regulatory domain is
2	selected from the	he grou	up consisting of a transcriptional activator, or a histone
3	acetyltransferas	se.	
1		48.	The method of claim 31, wherein the method further comprises the
2			ring to the cell a delivery vehicle comprising the zinc finger protein,
3			rehicle comprises a liposome or a membrane translocation
4	polypeptide.	irely ,	emote comprises a riposonic of a memorane transfocation
	herblede.		
1		49.	The method of claim 31, wherein the zinc finger protein is encoded
2	by a zinc finger	protei	n nucleic acid operably linked to a promoter, and wherein the
3	method further	compr	ises the step of first administering the nucleic acid to the cell in a
4	lipid:nucleic ac	id com	plex or as naked nucleic acid.
1	;	50.	The method of claim 31, wherein the zinc finger protein is encoded

by an expression vector comprising a zinc finger protein nucleic acid operably linked to a

- 1

2

1

2

- promoter, and wherein the method further comprises the step of first administering the
   expression vector to the cell.
- The method of claim 50, wherein the expression vector is a viral expression vector.
- The method of claim 50, wherein the expression vector is a retroviral expression vector, an adenoviral vector, a DNA plasmid vector, or an AAV expression vector.
- 1 53. The method of claim 50, wherein the zinc finger protein is encoded by a nucleic acid operably linked to an inducible promoter.
  - 54. The method of claim 50, wherein the zinc finger protein is encoded by a nucleic acid operably linked to a weak promoter.
- The method of claim 31, wherein the cell comprises less than about

  55. The method of claim 31, wherein the cell comprises less than about

  1.5x10<sup>6</sup> copies of the zinc finger protein.
- 1 56. The method of claim 31, wherein the target site is upstream of a transcription initiation site of the endogenous cellular gene.
  - 57. The method of claim 31, wherein the target site is adjacent to a transcription initiation site of the endogenous cellular gene.
- 1 58. The method of claim 31, wherein the target site is adjacent to an RNA polymerase pause site downstream of a transcription initiation site of the endogenous cellular gene.
- 1 59. The method of claim 31, wherein the zinc finger protein comprises
  2 an SP-1 backbone.
- 60. The method of claim 59, wherein the zinc finger protein comprises
   a regulatory domain and is humanized.
- 1 61. A method of modulating expression of an endogenous cellular gene 2 in a cell, the method comprising the step of:

71.

3	contacting a first target site	in the endogenous cellular gene with a first			
4	zinc finger protein;	zinc finger protein;			
5	thereby modulating expres	sion of the endogenous cellular gene.			
1		m 61, wherein the step of contacting further			
2	comprises contacting a second target site	in the endogenous cellular gene with a second			
3	zinc finger protein.				
1	63. The method of clai	m 62, wherein the first and second target sites			
2	are adjacent.				
1		m 63, wherein the first and second zinc finger			
2	proteins are covalently linked.				
1	65. The method of clai	m 61, wherein the first zinc finger protein is a			
2	fusion protein comprising a regulatory do	main.			
1		m 65, wherein the first zinc finger protein is a			
2	fusion protein comprising at least two reg	ulatory domains.			
1		m 62, wherein the first and second zinc finger			
2	proteins are fusion proteins, each compris	sing a regulatory domain.			
1	68. The method of claim	m 67, wherein the first and second zinc finger			
2	protein are fusion proteins, each compris-	ng at least two regulatory domains.			
1	69. A method of modu	lating expression of an endogenous cellular gene			
2	in a cell, the method comprising the step	of:			
3	contacting a target site in	he endogenous cellular gene with a fusion zinc			
4	finger protein comprising six fingers and	a regulatory domain;			
5	thereby modulating expre	ssion of the endogenous cellular gene.			
1	70. The method of cla	im 61, wherein the cell is selected from the			
2	group consisting of animal cell, a plant c	ell, a bacterial cell, a protozoal cell, or a fungal			
3	cell.				

The method of claim 70, wherein the cell is a mammalian cell

1	72.	The method of claim 71, wherein the cell is a human cell.	
1	73.	The method of claim 61, wherein the endogenous cellular gene is a	
2	selected from the g	roup consisting of VEGF, ERα, IGF-I, c-myc, c-myb, ICAM,	
3	_	, EPO, GM-CSF, GDNF, and LDL-R.	
	,		
1	74.	The method of claim 61, wherein the endogenous cellular gene is	
2	VEGF.	* * * * * * * * * * * * * * * * * * *	
1	75.	The method of claim 65 or 67, wherein the regulatory domain is	
2	selected from the g	roup consisting of a transcriptional repressor, a transcriptional	
3	activator, an endon	uclease, a methyl transferase, a histone acetyltransferase, and a histone	
4	deacetylase.		
1	76.	The method of claim 61, wherein the method further comprises the	
2	step of first admini	stering to the cell a delivery vehicle comprising the zinc finger protein,	
3	wherein the deliver	y vehicle comprises a liposome or a membrane translocation	
4	polypeptide.		
1	77.	The method of claim 61, wherein the zinc finger protein is encoded	
2	by a zinc finger pro	stein nucleic acid operably linked to a promoter, and wherein the	
3	method further con	prises the step of first administering the nucleic acid to the cell in a	
4	lipid:nucleic acid complex or as naked nucleic acid.		
1	78.	The method of claim 61, wherein the zinc finger protein is encoded	
2	by an expression ve	ector comprising a zinc finger protein nucleic acid operably linked to a	
3	promoter, and wherein the method further comprises the step of first administering the		
4	expression vector to	o the cell.	
1	79.	The method of claim 78, wherein the expression vector is a viral	
2	expression vector.	The method of claim 70, wherein the expression vector is a vital	
-	expression vector.		
1	80.	The method of claim 78, wherein the expression vector is a	
2	retroviral expression	on vector, an adenoviral expression vector, a DNA plasmid expression	
3	vector, or an AAV	expression vector.	

- The method of claim 78, wherein the zinc finger protein is encoded 1 81. 2 by a nucleic acid operably linked to an inducible promoter. The method of claim 78, wherein the zinc finger protein is encoded 1 82. by a nucleic acid operably linked to a weak promoter. 2 The method of claim 61, wherein the cell comprises less than about 1 2 1.5x106 copies of the zinc finger protein. 84. The method of claim 61, wherein the target site is upstream of a 1 2 transcription initiation site of the endogenous cellular gene. The method of claim 61, wherein the target site is adjacent to a 1 85. 2 transcription initiation site of the endogenous cellular gene. 86. The method of claim 61, wherein the target site is adjacent to an 1 2 RNA polymerase pause site downstream of a transcription initiation site of the 3 endogenous cellular gene. 87. The method of claim 61, wherein the zinc finger protein comprises 1 2 an SP-1 backbone.
- 88. The method of claim 88, wherein the zinc finger protein comprises
   a regulatory domain and is humanized.